NASDAQ: PRPO

Precipio, Inc.

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for PRPO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Precipio, Inc. (NASDAQ: PRPO) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-21 15:21 UTC.

What Precipio, Inc. does

The company operates as a healthcare biotechnology firm focused on improving cancer diagnostics, particularly for hematologic malignancies. It operates two complementary business divisions within a single operating segment: a pathology services division that provides specialized cancer diagnostic testing to physicians and hospitals, and a products division that develops and commercializes proprietary diagnostic assays for use by other clinical laboratories.

Summarized from Precipio, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-15
Return on equity	1,571.48%

Charts

Charts are in the appInteractive charts for PRPO are available in Oxford Ledge.
Open PRPO in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-19

2026-10-19DirectorAward582$13.1K
2026-10-19DirectorAward122$2.7K
2026-07-16DirectorAward416$10.5K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

VANGUARD CAPITAL MANAGEMENT LLC46,148$1.14M+81.1%
BlackRock, Inc.34,655$858.1K+19.4%
Topline Capital Management, LLC24,624$615.6K-49.6%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-04-10AuditorChanges in registrant's certifying accountantMarcum LLPAuthoritativeSEC 8-K →
2025-01-21Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-01-02Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersChristina ValauriEstimatedSEC 8-K →

Company news

View all →

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio
Yahoo2026-09-11
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
zacks.com2026-08-21POS
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
zacks.com2026-05-22POS

Questions this page answers

What does Precipio, Inc. do?

The company operates as a healthcare biotechnology firm focused on improving cancer diagnostics, particularly for hematologic malignancies.

When did PRPO last file with the SEC?

Precipio, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 15:21 UTC. This page is also available as JSON at /api/data?ticker=PRPO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PRPO and 5,000+ tickers.

Create a free account — keep PRPO

For your agent

GET /api/data?ticker=PRPO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt